What is PTGX's P/E ratio?

PROTAGONIST THERAPEUTICS INC (PTGX) currently trades at a P/E ratio of 2,356.89.

PROTAGONIST THERAPEUTICS INC reports a Return on Equity (ROE) of -17.50%.

What is PTGX's dividend yield?

PROTAGONIST THERAPEUTICS INC offers a dividend yield of 0.00%.

What is PTGX's Quality Score?

Our AI rates PTGX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PTGX?

Our AI Timing Score for PTGX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PTGX belong to?

PROTAGONIST THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

PTGX (NASDAQ) Stock Analysis | PROTAGONIST THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

PTGX AI Analysis Summary

Our AI summary for PTGX: PROTAGONIST THERAPEUTICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 2,356.89, ROE of -17.50%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PTGX

PROTAGONIST THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 136.64

-2.00 (-1.44%) Day Change

Watchlist Portfolio Compare Chart

2,356.89

P/E

0.00

D/E

-17.5%

ROE

-16.5%

ROA

0.00%

Div Yield

-11.84

PEG

PROTAGONIST THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 136.64 Price -2.00 (-1.44%) Day Change	NEWS SCORE: 99

PTGX, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	136.64
PBV / Sector	13.60 / 5.20
Earning Per Share	-1.76

PE / Sector	2,356.89 / 19.97
PEG or PE/Growth / Sector	-11.84 / 1.22
Average 1M Daily Value	84.94 M
Average 1W Daily Value	62.31 M

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-154.88 / 98.71
NPM Average (%) / Sector	-194.05 / -1,721.76
NPM Change Average (%) / Sector	-202.88 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-16.45 / 27.02
ROA Average (%) / Sector	-14.15 / -368.17
ROA Change Average (%) / Sector	-122.78 / 5,404.12
ROE (%) / Sector	-17.50 / 3.47
ROE Average (%) / Sector	-15.72 / 6.51
ROE Change Average (%) / Sector	-125.52 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:21
Symbol	PTGX
Name	PROTAGONIST THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	64.31 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	8,916.13 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560

Phone: 510 474 0170

Website: https://www.protagonist-inc.com

Employees: 131

Sector: Healthcare >> Biotechnology

Description: Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.